

## Press Release

Gerresheimer AG  
Benrather Strasse 18 - 20  
40213 Düsseldorf  
Germany

Jens Kürten  
Director Corporate Communication & Marketing  
Telephone +49 211 6181-250  
Fax +49 211 6181-241  
E-Mail [j.kuerten@gerresheimer.com](mailto:j.kuerten@gerresheimer.com)  
Internet [www.gerresheimer.com](http://www.gerresheimer.com)

Updated version March 08, 2013

Updated: 2<sup>nd</sup> page, 3<sup>rd</sup> paragraph, last sentence

New: **“unlike in previous years”** and **“not payable tax free”**

February 14, 2013

---

## Gerresheimer records strong revenue growth in the 2012 financial year

- Revenues rise by 11.4% (9.8% at constant exchange rates) to EUR 1,219m
- Adjusted operating margin (adjusted EBITDA margin) amounts to 19.4%
- Net income grows by 22.2% to EUR 66.5m
- Proposed dividend of EUR 0.65 per share
- Presence in the emerging markets most recently expanded through two acquisitions in India

Düsseldorf, February 14, 2013 – Gerresheimer AG, one of the leading worldwide partners of the pharma and healthcare industry, has closed the 2012 financial year with significant growth in revenues and profits. “We achieved all our targets in 2012. We recorded another year of strong growth in our business activities with the pharmaceutical sector, which once again proved to be relatively immune to cyclical effects. We are investing heavily in expanding our production capacity for medical devices such as prefilled glass syringes, insulin pens and inhalers. We are also focusing on the fast-growing emerging markets, especially in China, Brazil and India. In 2012 we succeeded in expanding our position in India in particular with the acquisition of two companies there,” says Uwe Röhrhoff, CEO of Gerresheimer AG.

In the 2012 financial year (December 1, 2011 to November 30, 2012), Gerresheimer recorded substantial growth in revenues of 11.4%. Revenues rose to EUR 1,219.1m. At constant exchange rates, revenues increased by 9.8%. In particular Gerresheimer achieved strong growth in the pharma segment coupled with good revenue results in the cosmetic glass business and the life science research segment.

Gerresheimer increased its operating result (adjusted EBITDA) by 8.8% to EUR 236.5m in the 2012 financial year. The adjusted EBITDA margin amounts to 19.4%, compared to prior year’s 19.9%. Net income rose by 22.2% to EUR 66.5m. Earnings per share rose by 19.3% to EUR 1.92. Adjusted earnings per share increased by 4.9% to EUR 2.56.

Gerresheimer invested EUR 118.9m in the 2012 financial year (up from EUR 86.2m in 2011). The company is expanding its production capacity for so-called medical devices, i.e. products for drug delivery such as

## Press Release

Gerresheimer AG  
Benrather Strasse 18 - 20  
40213 Düsseldorf  
Germany

Jens Kürten  
Director Corporate Communication & Marketing  
Telephone +49 211 6181-250  
Fax +49 211 6181-241  
E-Mail [j.kuerten@gerresheimer.com](mailto:j.kuerten@gerresheimer.com)  
Internet [www.gerresheimer.com](http://www.gerresheimer.com)

Updated version March 08, 2013

Updated: 2<sup>nd</sup> page, 3<sup>rd</sup> paragraph, last sentence

New: "unlike in previous years" and "not payable tax free"

### February 14, 2013

---

prefilled glass syringes, insulin pens and asthma inhalers, in Germany, Czech Republic and elsewhere. The Company is also focusing on growth in the emerging markets. In April 2012 Gerresheimer acquired Neutral Glass, one of India's leading manufacturers of pharmaceutical vials. This was followed in December 2012 by the acquisition of the Indian company Triveni, the regional market leader for plastic pharmaceutical packaging and closures. Gerresheimer intends to achieve both organic growth and growth through acquisitions in the future.

#### Outlook

Gerresheimer is expecting growth in revenues at constant exchange rates of five to six percent for the financial year 2013. The Company expects an adjusted EBITDA margin on prior year level (2012: 19.4%). Due to the good growth perspectives the investment volume of the financial year 2013 will be on the same level as the financial year just passed (2012: EUR 119m).

"2012 was a good year for Gerresheimer AG. As in the past, we want our shareholders to participate in the positive development of our business," said Uwe Röhrhoff. The Management and Supervisory Boards have agreed to propose a dividend of EUR 0.65 per share for the financial year 2012 at the Annual General Meeting on April 18, 2013. This represents a dividend ratio of 25 % of adjusted net income. Unlike in previous years this year's dividends are not payable tax-free to shareholders resident in Germany due to Gerresheimer AG's tax situation.

#### About Gerresheimer

Gerresheimer is an internationally leading manufacturer of high-quality specialty products made of glass and plastic for the global pharma and healthcare industry. Our comprehensive portfolio of products extends from pharmaceutical vials to complex drug delivery systems such as syringe systems, insulin pens and inhalers for safe medication dosage and application. Together with our partners, we develop solutions which set standards and have role model status in their respective market sectors.

Our Group realizes revenues of around EUR 1.2 bn and has approximately 11,000 employees at 47 locations in Europe, North and South America and Asia. We use first-rate technologies, convincing innovations and targeted investments to systematically consolidate our strong market position.

## Press Release

Gerresheimer AG  
Benrather Strasse 18 - 20  
40213 Düsseldorf  
Germany

Jens Kürten  
Director Corporate Communication & Marketing  
Telephone +49 211 6181-250  
Fax +49 211 6181-241  
E-Mail [j.kuerten@gerresheimer.com](mailto:j.kuerten@gerresheimer.com)  
Internet [www.gerresheimer.com](http://www.gerresheimer.com)

Updated version March 08, 2013

Updated: 2<sup>nd</sup> page, 3<sup>rd</sup> paragraph, last sentence

New: "unlike in previous years" and "not payable tax free"

February 14, 2013

The online annual report is available at:  
<http://annualreport2012.gerresheimer.com>

#### Media Contact

Jens Kürten  
Director Corporate Communication & Marketing  
Phone +49 211 6181-250  
Fax +49 211 6181-241  
E-Mail [j.kuerten@gerresheimer.com](mailto:j.kuerten@gerresheimer.com)

#### Investor Relations & Creditor Relations Contact

Anke Linnartz  
Director Corporate Investor Relations & Creditor Relations  
Phone +49 211 6181-314  
Fax +49 211 6181-121  
E-Mail [a.linnartz@gerresheimer.com](mailto:a.linnartz@gerresheimer.com)

### Group Key Figures (IFRS; Financial Year end November 30)

in EUR million	FY 2012	FY 2011	Change in %
Revenues	1,219.1	1,094.7	+11.4
at constant exchange rates			+9.8
Adjusted EBITDA <sup>1</sup>	236.5	217.3	+8.8
in % of revenues	19.4	19.9	
Profit from operations (EBIT)	128.4	109.3	+17.5
Net income	66.5	54.4	+22.2
Adjusted net income <sup>2</sup>	86.5	80.6	+7.3
Earnings per share in EUR	1.92	1.61	+19.3
Adjusted earnings per share <sup>3</sup> in EUR	2.56	2.44	+4.9
Dividend per share in EUR	0.65 <sup>4</sup>	0.60	+8.3
Equity ratio in %	37.2	36.4	
Net financial debt	366.5	364.6	+0.5
Capital expenditure	118.9	86.2	+37.9

<sup>1</sup> Adjusted EBITDA: Earnings before income taxes, financial result, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses.

<sup>2</sup> Adjusted net income: Consolidated profit (including profit attributable to non-controlling interests) before non-cash amortization of fair value adjustments, special effects from restructuring expenses, extraordinary depreciation, one-off costs connected with the refinancing in the financial year 2011, the balance of one-off income and expenses (including significant non-cash expenses) and the related tax effects.

<sup>3</sup> Adjusted net income after non-controlling interests divided by 31.4m shares.

<sup>4</sup> Proposed appropriation of net earnings.

## Press Release

Gerresheimer AG  
Benrather Strasse 18 - 20  
40213 Düsseldorf  
Germany

Jens Kürten  
Director Corporate Communication & Marketing  
Telephone +49 211 6181-250  
Fax +49 211 6181-241  
E-Mail [j.kuerten@gerresheimer.com](mailto:j.kuerten@gerresheimer.com)  
Internet [www.gerresheimer.com](http://www.gerresheimer.com)

Updated version March 08, 2013

Updated: 2<sup>nd</sup> page, 3<sup>rd</sup> paragraph, last sentence

New: "unlike in previous years" and "not payable tax free"

February 14, 2013

### Group Key Figures (IFRS; Financial Year end November 30)

in EUR million	Q4 2012	Q4 2011	Change in %
Revenues	324.9	288.4	+12.7
at constant exchange rates			+11.8
Adjusted EBITDA <sup>1</sup>	72.8	62.2	+17.0
in % of revenues	22.4	21.6	
Profit from operations (EBIT)	47.2	30.9	+52.8
Net income	27.9	15.0	+86.0
Adjusted net income <sup>2</sup>	33.3	24.2	+37.6
Earnings per share in EUR	0.84	0.46	+82.6
Adjusted earnings per share <sup>3</sup> in EUR	1.00	0.75	+33.3
Capital expenditure	49.3	39.0	+26.4

<sup>1</sup> Adjusted EBITDA: Earnings before income taxes, financial result, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses.

<sup>2</sup> Adjusted net income: Consolidated profit (including profit attributable to non-controlling interests) before non-cash amortization of fair value adjustments, special effects from restructuring expenses, extraordinary depreciation, one-off costs connected with the refinancing in the financial year 2011, the balance of one-off income and expenses (including significant non-cash expenses) and the related tax effects.

<sup>3</sup> Adjusted net income after non-controlling interests divided by 31.4m shares.